SCHEDULE 13G: Goldman Sachs Discloses 5.2% Passive Stake in AnaptysBio Inc.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a passive beneficial ownership of 5.2% in AnaptysBio, Inc.'s common stock.

Summary

• The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly filed a Schedule 13G, indicating their beneficial ownership in AnaptysBio, Inc.
• The reporting persons collectively beneficially own 1,588,653.95 shares of AnaptysBio, Inc. common stock.
• This ownership represents 5.2% of the total class of AnaptysBio, Inc. common stock.
• The ownership is characterized by shared voting power and shared dispositive power over 1,588,305.95 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of AnaptysBio, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership by a large financial institution, indicating a passive investment without intent to influence control. It does not contain performance data or forward-looking statements to assess sentiment beyond neutrality.

Positives

• The disclosure of a significant passive stake (5.2%) by a major financial institution like Goldman Sachs could be interpreted by the market as a vote of confidence in AnaptysBio, Inc.'s long-term prospects.
• The statement that the investment is held in the ordinary course of business indicates a standard portfolio allocation rather than an activist stance, which can be viewed as a stable, non-disruptive investment.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding AnaptysBio, Inc.'s future performance or outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard beneficial ownership disclosure and does not provide specific industry context or trends related to AnaptysBio, Inc. or its sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by a prominent financial institution like Goldman Sachs could be perceived positively by existing and potential shareholders, potentially signaling institutional confidence in AnaptysBio, Inc.

Key Dates

Keywords

AnaptysBio, Inc., Goldman Sachs Group, Goldman Sachs & Co. LLC, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, SEC Filing